MedMira Moves Forward with Outsourced Manufacturing Strategy

    HALIFAX, Jan. 28 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, today announced its plans to move forward with an outsourced
manufacturing strategy. Using an outsourced manufacturing model MedMira can
answer the demand and price complexities in high volume markets such as
Africa, Asia, and Latin America and capitalize on new opportunities for OEM
    MedMira will outsource manufacturing of basic components and product
assembly of its rapid diagnostic kits to strategic partner Shenzhen Kang Sheng
Bao Bio-Technology Co., Ltd. ("KSB"), a GMP and ISO certified biotech company
specializing in manufacturing and distribution of in vitro diagnostic kits.
KSB is one of the China portfolio companies of Morningside Group, a major
MedMira investor. MedMira continues its focus on technology and product
development as well as the manufacturing of key biochemical components used in
the Company's rapid tests.
    "We have worked with KSB over the past several months, taking the
necessary time to ensure a seamless transfer of the manufacturing knowledge
base. This transition to an outsourced manufacturing model will provide clear
benefits to MedMira and our customers across the globe. It allows us to focus
on our core competency of developing innovative diagnostic solutions on the
award-winning rapid flow-through technology platform," said Hermes Chan,
president and CEO, MedMira Inc. "Teaming with a world class manufacturing
organization like KSB, better positions MedMira to deliver high quality
products to markets where price is the determining factor in nearly all
purchasing decisions."
    The rapid tests being manufactured through this partnership will answer
the demand for high quality, low cost rapid diagnostics for HIV, Hepatitis and
other infectious and sexually transmitted diseases. KSB has met and exceeded
all of MedMira's stringent quality requirements and test batches have been
evaluated by MedMira's own quality assurance team to ensure continued customer
    Chan continued, "We believe that our high quality products together with
a variable pricing structure will give us the competitive edge needed to
compete in today's global markets."

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E

For further information:

For further information: MedMira Contacts: Dr. James Smith, Investor
Relations & Corporate Affairs, (902) 450-1588,; Andrea Young,
Corporate Communications, (902) 450-1588,

Organization Profile

MedMira Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890